352 related articles for article (PubMed ID: 32943544)
1. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
[TBL] [Abstract][Full Text] [Related]
2. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
4. TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various
Ito K; Nishio M; Kato M; Murakami H; Aoyagi Y; Ohe Y; Okayama T; Hashimoto A; Ohsawa H; Tanaka G; Nonoshita K; Ito S; Matsuo K; Miyadera K
Mol Cancer Ther; 2019 May; 18(5):920-928. PubMed ID: 30872380
[TBL] [Abstract][Full Text] [Related]
5. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant
Udagawa H; Hasako S; Ohashi A; Fujioka R; Hakozaki Y; Shibuya M; Abe N; Komori T; Haruma T; Terasaka M; Fujita R; Hashimoto A; Funabashi K; Yasuda H; Miyadera K; Goto K; Costa DB; Kobayashi SS
Mol Cancer Res; 2019 Nov; 17(11):2233-2243. PubMed ID: 31467113
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
Masood A; Kancha RK; Subramanian J
Semin Oncol; 2019 Jun; 46(3):271-283. PubMed ID: 31558282
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS
J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
9. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
Soo RA; de Marinis F; Han JY; Ho JC; Martin E; Servidio L; Sandelin M; Popat S
Clin Lung Cancer; 2024 Jan; 25(1):80-84. PubMed ID: 37914594
[TBL] [Abstract][Full Text] [Related]
10. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
11. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
13. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC
Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498
[TBL] [Abstract][Full Text] [Related]
14. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
15. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
16. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
17. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
Pang L; Huang Y; Zhuang W; Zhang Y; Liao J; Hao Y; Hao F; Wang G; Chen ZC; Zhu Y; Li M; Song Z; Deng BP; Li J; Zhang L; Fang W
Clin Cancer Res; 2024 Jun; 30(12):2636-2646. PubMed ID: 38578683
[TBL] [Abstract][Full Text] [Related]
18. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
19. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report.
Cai Y; Wang Y; Sun J; Wang X; Xu Y; Sun C; Guo Y; Sun M; Ma K
J Int Med Res; 2020 Jun; 48(6):300060520928793. PubMed ID: 32493093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]